Overview Financials News + Filings Key Docs Ownership Insiders
|
|
Centessa Pharmaceuticals plc
|
|
| Common Size Income Statement |
|
|
|
|
Annual | Quarterly | TTM |
|
| In millions, except per share items | Jun-30-23 | Mar-31-23 | Jun-30-22 | Mar-31-22 | Dec-31-21 | Sep-30-21 | Jun-30-21 | Dec-31-20 |
| | 10-Q | 10-Q | 10-Q | 10-Q | 8-K | 10-Q | 10-Q | 10-K |
| Revenues | | | | 100.0% | 100.0% | | 100.0% | |
| Cost of goods sold | | | | 0.0% | 209.1% | | 0.0% | |
| Gross profit | | | | 100.0% | -109.1% | | 100.0% | |
| Research and development | | | | -1861.3% | | | -160.3% | |
| General and administrative | | | | -726.5% | 31.3% | | -104.7% | |
| EBITDA | | | | 2686.4% | -140.3% | | 365.0% | |
| Depreciation | | | | -1.4% | | | | |
| EBIT | | | | 2687.8% | -140.3% | | 365.0% | |
| Pre-tax income | | | | 2748.4% | -146.0% | | 366.4% | |
| Income taxes | | | | -4.0% | 0.3% | | 0.0% | |
| Net income | | | | 2752.4% | -146.3% | | 366.4% | |
|